Evidence map›Paper›PMID 40718780›Full record

ArticlePeerJ2025

Tertiary lymphoid structures-driven immune infiltration patterns and their association with survival in neuroblastoma.

Xuelian Liu, Jian Deng, Bingqing Yu, Jiaxiong Tan, Xiaoliang Lu, Minmin Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xuelian Liu *Department of Gastroenterology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Jian Deng *Department of Gastroenterology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Bingqing YuDepartment of Gastroenterology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Jiaxiong TanDepartment of Pediatric Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.ORCID 0000-0002-5606-3962
Xiaoliang LuDepartment of Gastroenterology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Minmin ZhangDepartment of Gastroenterology, The First Affiliated Hospital of Jinan University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Neuroblastoma (NB), a diverse childhood cancer, needs better prognostic markers for personalized treatment. The current clinical risk stratification system does not fully explain the high heterogeneity of tumor patients. Tertiary lymphoid structures (TLS), key in tumor immunity, may serve as new biomarkers, but their impact on NB prognosis is unclear. Methods: We combined transcriptome data from NB cohorts GSE49710 and GSE62564, analyzing 37 TLS-related genes. A prognostic signature (CMLS) was created using machine learning and validated with Kaplan-Meier and receiver operating characteristic (ROC) curves. We also studied immune infiltration and gene expression patterns in NB tissues using single-cell sequencing and quantitative real-time polymerase chain reaction (qRT-PCR). Results: A 6-gene TLS signature predicted better survival in NB patients. High levels of CCL2, CCL4, CCL21, CD200, CXCR3, and IGSF6 correlated with improved survival. The low-TLS risk group showed better event-free and overall survival. Immune analysis indicated a higher immune cell presence, especially cytotoxic T cells, in this group. Single-cell sequencing revealed lower TLS gene expression in refractory recurrence samples. CD200 downregulation reduced NB cell invasiveness and migration. Conclusion: Our study demonstrates that TLS-related genes play a crucial role in NB prognosis, with a 6-gene TLS signature (CCL2, CCL4, CCL21, CD200, CXCR3, and IGSF6) serving as a promising prognostic biomarker for NB. CD200 may be a potential target for inhibiting the biological behavior of NB cells.

Indexed as

NeuroblastomaTertiary Lymphoid StructuresBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansMalePrognosisTranscriptomeBiomarkers, TumorConsensus machine learning-driven signatureNeuroblastomaSingle-cell sequencingTertiary lymphoid structuresTumor microenvironment

Identifiers

PMID40718780
PMCPMC12292307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.